title: Injectable in situ forming controlled release implant composed of a poly-ether-ester-carbonate and applications in the field of chemotherapy.
abstract: Polymeric controlled delivery systems hold great promise in the field of modern medicine. Such technology has already been converted into commercially viable products in a myriad of fields. Chemotherapy is an example of such an area where constant efficacious levels of drug can greatly enhance clinical outcomes. The key to designing such therapies is the preparation of the proper delivery system. To this end, a series of bioresorbable polyether-ester-carbonate copolymers have been developed, which when combined with a diluent, are capable injection into the body and consistently forming a drug delivery depot. The study delineated here aimed at producing a more effective treatment of a common drug, paclitaxel, using the polymeric carrier. The polymer carrier system exhibited controlled release of paclitaxel both in vitro and in vivo. Drug concentrations were analyzed by high performance liquid chromatography and apoptotic activity was confirmed through flow cytometry. Relevant success was exhibited by the regression of tumor size following a multiple injection treatment regimen in a murine xenograft model. This multiple injection treatment shows promising results when compared to the traditional paclitaxel paradigm of a single injection for a period of 3 weeks.
authors.affiliation: Poly-Med, Inc., Anderson, South Carolina 29625, USA. Jason.Olbrich@poly-med.com
authors.forename: Jason M
authors.initials: JM
authors.lastname: Olbrich
authors.forename: Patilee L
authors.initials: PL
authors.lastname: Tate
authors.forename: Joel T
authors.initials: JT
authors.lastname: Corbett
authors.forename: James M
authors.initials: JM
authors.lastname: Lindsey
authors.forename: Sheila D
authors.initials: SD
authors.lastname: Nagatomi
authors.forename: Waleed S W
authors.initials: WS
authors.lastname: Shalaby
authors.forename: Shalaby W
authors.initials: SW
authors.lastname: Shalaby
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002254:Carbonates / Q000737:chemistry*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy; D045744:Cell Line, Tumor; D003692:Delayed-Action Preparations / Q000737:chemistry*; D005260:Female; D007267:Injections; D008175:Lung Neoplasms / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D002254:Carbonates; D003692:Delayed-Action Preparations; D017239:Paclitaxel